Table of Content

1 Key Insights

2 Report Introduction

3 Functional Dyspepsia Market Overview at a Glance
3.1 Market Share (%) Distribution of Functional Dyspepsia in 2018
3.2 Market Share (%) Distribution of Functional Dyspepsia in 2030

4 Executive Summary of Functional Dyspepsia

5 Disease Background and Overview
1.1 Introduction
1.2 Clinical Manifestations
1.3 Risk Factors
1.4 Pathogenesis
1.5 Subtypes
1.6 Diagnosis
1.6.1 Guidelines for Diagnosis
1.7 Differential Diagnosis
1.8 Treatment and Management
1.8.1 Treatment Guidelines

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Population of Functional Dyspepsia
6.3 Epidemiology of Functional Dyspepsia
6.4 The United States
6.4.1 Prevalent Cases of Functional Dyspepsia in the United States
6.4.2 Type-specific cases of Functional Dyspepsia in the United States
6.4.3 Age-specific Cases of Functional Dyspepsia in the United States
6.4.4 Gender-specific cases of Functional Dyspepsia in the United States
6.5 EU5
6.5.1 Germany
6.5.2 France
6.5.3 Italy
6.5.4 Spain
6.5.5 The United Kingdom
6.6 Japan
6.6.1 Prevalent Cases of Functional Dyspepsia in Japan
6.6.2 Type-specific cases of Functional Dyspepsia in Japan
6.6.3 Age-specific Cases of Functional Dyspepsia in Japan
6.6.4 Gender-specific cases of Functional Dyspepsia in Japan

7 Organizations contributing towards Functional Dyspepsia

8 Case Reports

9 Patient Journey

10 Marketed Therapies
10.1 ACOFIDE: Astellas Pharma & Zeria Pharmaceuticals
10.1.1 Product Description
10.1.2 Mechanism of action
10.1.3 Regulatory Milestones
10.1.4 Other Development Activities
10.1.5 Safety and Efficacy of Acofide
10.1.6 Side effects of ACOFIDE
10.1.7 Product Profile

11 Emerging Therapies
11.1.1 Other developmental assets
11.2 Motilitone (DA-9701): Dong-A ST
11.2.1 Drug Description
11.2.2 Clinical Development
11.2.3 Clinical Trials Information
11.2.4 Product Profile

12 Functional Dyspepsia: 7 Major Market Analysis
12.1 Key Findings
12.2 Market Size of Functional Dyspepsia in 7MM
12.3 Market Outlook
12.4 United States Market Size
12.4.1 Total Market Size of Functional Dyspepsia in the United States
12.4.2 Market Size of Functional Dyspepsia by Therapies
12.5 EU-5 Market
12.5.1 Germany
12.5.2 France
12.5.3 Italy
12.5.4 Spain
12.5.5 United Kingdom
12.6 Japan Market Size
12.6.1 Total Market Size of Functional Dyspepsia in Japan
12.6.2 Market Size of Functional Dyspepsia by Therapies in Japan

13 Market Drivers

14 Market Barriers

15 SWOT Analysis

16 Unmet Needs

17 KOL Views

18 Appendix
18.1 Bibliography
18.2 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight



List of Figures

Figure 1: Clinical Manifestations in Functional Dyspepsia
Figure 2: Risk factors Involved in Functional Dyspepsia
Figure 3: Various Mechanisms Involved in the Pathogenesis of Functional Dyspepsia
Figure 4: Subtypes of Functional Dyspepsia
Figure 5: Rome III Diagnostic Criteria for Functional Dyspepsia
Figure 6: Rome IV Diagnostic Criteria for Functional Dyspepsia
Figure 7: Differential Diagnosis of Functional Dyspepsia
Figure 8: Management Algorithm of Functional Dyspepsia
Figure 9: ACG/CAG Treatment Guidelines- Recommendations for Functional Dyspepsia
Figure 10: Total Prevalent Population of Functional Dyspepsia in 7MM in 000s (2018–2030)
Figure 11: Prevalence of Functional Dyspepsia and subtypes using symptom-based criteria (Rome IV)
Figure 12: Prevalent Cases of Functional Dyspepsia in the United States in 000s (2018–2030)
Figure 13: Type-specific cases of Functional Dyspepsia in the United States in 000s (2018–2030)
Figure 14: Age-specific Cases of Functional Dyspepsia in the United States in 000s (2018–2030)
Figure 15: Gender-specific cases of Functional Dyspepsia in the United States in 000s (2018–2030)
Figure 16: Prevalent Cases of Functional Dyspepsia in Germany in 000s (2018–2030)
Figure 17: Type-specific cases of Functional Dyspepsia in Germany in 000s (2018–2030)
Figure 18: Age-specific Cases of Functional Dyspepsia in Germany in 000s (2018–2030)
Figure 19: Gender-specific cases of Functional Dyspepsia in Germany in 000s (2018–2030)
Figure 20: Prevalent Cases of Functional Dyspepsia in France in 000s (2018–2030)
Figure 21: Type-specific cases of Functional Dyspepsia in France in 000s (2018–2030)
Figure 22: Age-specific Cases of Functional Dyspepsia in France in 000s (2018–2030)
Figure 23: Gender-specific cases of Functional Dyspepsia in France in 000s (2018–2030)
Figure 24: Prevalent Cases of Functional Dyspepsia in Italy in 000s (2018–2030)
Figure 25: Type-specific cases of Functional Dyspepsia in Italy in 000s (2018–2030)
Figure 26: Age-specific Cases of Functional Dyspepsia in Italy in 000s (2018–2030)
Figure 27: Gender-specific cases of Functional Dyspepsia in Italy in 000s (2018–2030)
Figure 28: Prevalent Cases of Functional Dyspepsia in Spain in 000s (2018–2030)
Figure 29: Type-specific cases of Functional Dyspepsia in Spain in 000s (2018–2030)
Figure 30: Age-specific Cases of Functional Dyspepsia in Spain in 000s (2018–2030)
Figure 31: Gender-specific cases of Functional Dyspepsia in Spain in 000s (2018–2030)
Figure 32: Prevalent Cases of Functional Dyspepsia in the United Kingdom in 000s (2018–2030)
Figure 33: Type-specific cases of Functional Dyspepsia in the United Kingdom in 000s (2018–2030)
Figure 34: Age-specific Cases of Functional Dyspepsia in the United Kingdom in 000s (2018–2030)
Figure 35: Gender-specific cases of Functional Dyspepsia in the United Kingdom in 000s (2018–2030)
Figure 36: Prevalent Cases of Functional Dyspepsia in Japan in 000s (2018–2030)
Figure 37: Type-specific cases of Functional Dyspepsia in Japan in 000s (2018–2030)
Figure 38: Age-specific Cases of Functional Dyspepsia in Japan in 000s (2018–2030)
Figure 39: Gender-specific cases of Functional Dyspepsia in Japan in 000s (2018–2030)
Figure 40: 7 Major Market Size of Functional Dyspepsia in USD million (2018–2030)
Figure 41: The US Market Size of Functional Dyspepsia in USD million (2018–2030)
Figure 42: The US Market Size of Functional Dyspepsia by Therapies (2018–2030)
Figure 43: The Germany Market Size of Functional Dyspepsia in USD million (2018–2030)
Figure 44: The Germany Market Size of Functional Dyspepsia by Therapies (2018–2030)
Figure 45: The France Market Size of Functional Dyspepsia in USD million (2018–2030)
Figure 46: The France Market Size of Functional Dyspepsia by Therapies (2018–2030)
Figure 47: The Italy Market Size of Functional Dyspepsia in USD million (2018–2030)
Figure 48: The Italy Market Size of Functional Dyspepsia by Therapies (2018–2030)
Figure 49: The Spain Market Size of Functional Dyspepsia in USD million (2018–2030)
Figure 50: The Spain Market Size of Functional Dyspepsia by Therapies (2018–2030)
Figure 51: The United Kingdom Market Size of Functional Dyspepsia in USD million (2018–2030)
Figure 52: The United Kingdom Market Size of Functional Dyspepsia by Therapies (2018–2030)
Figure 53: The Japan Market Size of Functional Dyspepsia in USD million (2018–2030)
Figure 54: The Japan Market Size of Functional Dyspepsia by Therapies (2018–2030)
Figure 55: Overlapping symptoms and pathophysiology of Functional Dyspepsia, IBS, and GERD

List of Tables

Table 1: Summary of Functional Dyspepsia, Market, Epidemiology, and Key Events (2018–2030)
Table 2: Investigations for the Work-up of Functional Dyspepsia With Their Strengths and Weaknesses
Table 3: Total Prevalent Population of Functional Dyspepsia in 7MM in 000s (2018–2030)
Table 4: Prevalent Cases of Functional Dyspepsia in the United States in 000s (2018–2030)
Table 5: Type-specific cases of Functional Dyspepsia in the United States in 000s (2018–2030)
Table 6: Age-specific Cases of Functional Dyspepsia in the United States in 000s (2018–2030)
Table 7: Gender-specific cases of Functional Dyspepsia in the United States in 000s (2018–2030)
Table 8: Prevalent Cases of Functional Dyspepsia in Germany in 000s (2018–2030)
Table 9: Type-specific cases of Functional Dyspepsia in Germany in 000s (2018–2030)
Table 10: Age-specific Cases of Functional Dyspepsia in Germany in 000s (2018–2030)
Table 11: Gender-specific cases of Functional Dyspepsia in Germany in 000s (2018–2030)
Table 12: Prevalent Cases of Functional Dyspepsia in France in 000s (2018–2030)
Table 13: Type-specific cases of Functional Dyspepsia in France in 000s (2018–2030)
Table 14: Age-specific Cases of Functional Dyspepsia in France in 000s (2018–2030)
Table 15: Gender-specific cases of Functional Dyspepsia in France in 000s (2018–2030)
Table 16: Prevalent Cases of Functional Dyspepsia in Italy in 000s (2018–2030)
Table 17: Type-specific cases of Functional Dyspepsia in Italy in 000s (2018–2030)
Table 18: Age-specific Cases of Functional Dyspepsia in Italy in 000s (2018–2030)
Table 19: Gender-specific cases of Functional Dyspepsia in Italy in 000s (2018–2030)
Table 20: Prevalent Cases of Functional Dyspepsia in Spain in 000s (2018–2030)
Table 21: Type-specific cases of Functional Dyspepsia in Spain in 000s (2018–2030)
Table 22: Age-specific Cases of Functional Dyspepsia in Spain in 000s (2018–2030)
Table 23: Gender-specific cases of Functional Dyspepsia in Spain in 000s (2018–2030)
Table 24: Prevalent Cases of Functional Dyspepsia in the United Kingdom in 000s (2018–2030)
Table 25: Type-specific cases of Functional Dyspepsia in the United Kingdom in 000s (2018–2030)
Table 26: Age-specific Cases of Functional Dyspepsia in the United Kingdom in 000s (2018–2030)
Table 27: Gender-specific cases of Functional Dyspepsia in the United Kingdom in 000s (2018–2030)
Table 28: Prevalent Cases of Functional Dyspepsia in Japan in 000s (2018–2030)
Table 29: Type-specific cases of Functional Dyspepsia in Japan in 000s (2018–2030)
Table 30: Age-specific Cases of Functional Dyspepsia in Japan in 000s (2018–2030)
Table 31: Gender-specific cases of Functional Dyspepsia in Japan in 000s (2018–2030)
Table 32: Organizations Contributing Toward the Fight Against Functional Dyspepsia
Table 33: Motilitone, Clinical Trial Description, 2021
Table 34: 7 Major Market Size of Functional Dyspepsia in USD million (2018–2030)
Table 35: The US Market Size of Functional Dyspepsia in USD million (2018–2030)
Table 36:The US Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)
Table 37: The Germany Market Size of Functional Dyspepsia in USD million (2018–2030)
Table 38:The Germany Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)
Table 39: The France Market Size of Functional Dyspepsia in USD million (2018–2030)
Table 40:The France Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)
Table 41: The Italy Market Size of Functional Dyspepsia in USD million (2018–2030)
Table 42:The Italy Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)
Table 43: The Spain Market Size of Functional Dyspepsia in USD million (2018–2030)
Table 44:The Spain Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)
Table 45: The United Kingdom Market Size of Functional Dyspepsia in USD million (2018–2030)
Table 46:The United Kingdom Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)
Table 47: The Japan Market Size of Functional Dyspepsia in USD million (2018–2030)
Table 48:The Japan Market Size of Functional Dyspepsia by Therapies in USD million (2018–2030)